These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30301885)

  • 1. Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors.
    Gara SK; Lack J; Zhang L; Harris E; Cam M; Kebebew E
    Nat Commun; 2018 Oct; 9(1):4172. PubMed ID: 30301885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape.
    Fojo T; Huff L; Litman T; Im K; Edgerly M; Del Rivero J; Pittaluga S; Merino M; Bates SE; Dean M
    BMC Med Genomics; 2020 Nov; 13(1):165. PubMed ID: 33148256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.
    Juhlin CC; Goh G; Healy JM; Fonseca AL; Scholl UI; Stenman A; Kunstman JW; Brown TC; Overton JD; Mane SM; Nelson-Williams C; Bäckdahl M; Suttorp AC; Haase M; Choi M; Schlessinger J; Rimm DL; Höög A; Prasad ML; Korah R; Larsson C; Lifton RP; Carling T
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E493-502. PubMed ID: 25490274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
    Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
    J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ENDOCRINE TUMOURS: The genomics of adrenocortical tumors.
    Faillot S; Assie G
    Eur J Endocrinol; 2016 Jun; 174(6):R249-65. PubMed ID: 26739091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular markers and targeted therapies for adrenocortical carcinoma.
    Xu Y; Qi Y; Zhu Y; Ning G; Huang Y
    Clin Endocrinol (Oxf); 2014 Feb; 80(2):159-68. PubMed ID: 24304415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
    Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
    Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas.
    Ragazzon B; Libé R; Assié G; Tissier F; Barreau O; Houdayer C; Perlemoine K; Audebourg A; Clauser E; René-Corail F; Bertagna X; Dousset B; Bertherat J; Groussin L
    Eur J Endocrinol; 2014 Mar; 170(3):385-91. PubMed ID: 24347427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer.
    De Martino MC; Al Ghuzlan A; Aubert S; Assié G; Scoazec JY; Leboulleux S; Do Cao C; Libè R; Nozières C; Lombès M; Pattou F; Borson-Chazot F; Hescot S; Mazoyer C; Young J; Borget I; Colao A; Pivonello R; Soria JC; Bertherat J; Schlumberger M; Lacroix L; Baudin E
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4080-8. PubMed ID: 23979958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical management of adrenocortical carcinoma.
    Ranvier GG; Inabnet WB
    Endocrinol Metab Clin North Am; 2015 Jun; 44(2):435-52. PubMed ID: 26038210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosome 19 amplification correlates with advanced disease in adrenocortical carcinoma.
    Rubinstein JC; Brown TC; Goh G; Juhlin CC; Stenman A; Korah R; Carling T
    Surgery; 2016 Jan; 159(1):296-301. PubMed ID: 26453132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and characterization of the first pediatric adrenocortical carcinoma xenograft model identifies topotecan as a potential chemotherapeutic agent.
    Pinto EM; Morton C; Rodriguez-Galindo C; McGregor L; Davidoff AM; Mercer K; Debelenko LV; Billups C; Ribeiro RC; Zambetti GP
    Clin Cancer Res; 2013 Apr; 19(7):1740-7. PubMed ID: 23406775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
    Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
    Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel TP53 Mutation Associated with TWIST1 and SIP1 Expression in an Aggressive Adrenocortical Carcinoma.
    Bulzico D; Torres DC; Ferreira GM; Pires BRB; de Faria PAS; Hassan R; Abdelhay E; Vaisman M; Vieira Neto L
    Endocr Pathol; 2017 Dec; 28(4):326-331. PubMed ID: 28421464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC.
    Kar A; Zhang Y; Yacob BW; Saeed J; Tompkins KD; Bagby SM; Pitts TM; Somerset H; Leong S; Wierman ME; Kiseljak-Vassiliades K
    Endocr Relat Cancer; 2019 Oct; 26(10):765-778. PubMed ID: 31325906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MECHANISMS OF ENDOCRINOLOGY: Cell cycle regulation in adrenocortical carcinoma.
    Pereira SS; Monteiro MP; Bourdeau I; Lacroix A; Pignatelli D
    Eur J Endocrinol; 2018 Aug; 179(2):R95-R110. PubMed ID: 29773584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization.
    Stojadinovic A; Ghossein RA; Hoos A; Nissan A; Marshall D; Dudas M; Cordon-Cardo C; Jaques DP; Brennan MF
    J Clin Oncol; 2002 Feb; 20(4):941-50. PubMed ID: 11844815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas.
    Gupta S; Won H; Chadalavada K; Nanjangud GJ; Chen YB; Al-Ahmadie HA; Fine SW; Sirintrapun SJ; Strong VE; Raj N; Lagunes DR; Vanderbilt CM; Berger MF; Ladanyi M; Dogan S; Tickoo SK; Reuter VE; Gopalan A
    Endocr Pathol; 2022 Jun; 33(2):304-314. PubMed ID: 34549366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA copy amplification and overexpression of SLC12A7 in adrenocortical carcinoma.
    Brown TC; Juhlin CC; Healy JM; Stenman A; Rubinstein JC; Korah R; Carling T
    Surgery; 2016 Jan; 159(1):250-7. PubMed ID: 26454676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
    Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
    Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.